Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

42 results about "Globin genes" patented technology

Hemoglobins carry oxygen from the lungs to other tissues and are encoded by a family of globin genes that are differentially expressed during development. Defects in expression of these globin genes lead to inherited anemias called thalassemias.

Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

The disclosure features systems and methods for correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.
Owner:VERTEX PHARMACEUTICALS INC

Vectors combining Anti-sickling beta-as3-globin with anti bcel11a shrnamir to treat beta-hemoglobinopathies

In certain embodiments, a lentiviral vector for the treatment of sickle cell disease (SCD) is provided. In certain embodiments, the vector comprises an expression cassette that encodes that an anti-sickling β-globin gene and an shRNA that inhibits expression of a BCL11A gene (BCL11A shRNA) wherein said expression cassette is in reverse orientation in the vector; a β-globin locus control region (LCR) comprising a reduced length hypersensitive site 1 (HS1) sequence, a reduced length hypersensitive site 2 (HS2) sequence, a reduced length hypersensitive site 3 (HS3) sequence, and a reduced length hypersensitive site 4 (HS4) sequence, where said anti-sickling β-globin gene is operably linked to the human β-globin locus control region.
Owner:CHILDRENS MEDICAL CENT CORP +2

Hemoglobin fermented by engineered pichia pastoris and preparation method thereof

The invention discloses engineered pichia pastoris fermented hemoglobin and a preparation method thereof, and relates to the technical field of biology, the engineered pichia pastoris fermented hemoglobin is sourced from red beans, and a hemoglobin protein nucleotide sequence is shown as SEQ ID NO: 1; the construction of a VaHB globin synthesis pathway comprises the following steps: integrating a corresponding globin gene into a protein expression engineering strain, and then integrating a key enzyme gene of a heme synthesis pathway into a genome of a high-copy globin expression engineering strain, so as to obtain the HEM-ALL engineering strain. The fermentation preparation of the hemoglobin VaHB comprises the following steps: activating the HEM-ALL engineering strain, inoculating a liquid culture medium, then transferring a secondary seed of the liquid culture medium to a fermentation tank, and carrying out fed-batch fermentation through glycerol and methanol to obtain the hemoglobin VaHB. The hemoglobin is applied as a food coloring agent and a flavoring agent. The engineering pichia pastoris is used for identifying and intracellular producing hemoglobin VaHB, and expensive precursors do not need to be exogenously added.
Owner:SHANGHAI JIAOTONG UNIV

Application of thyroid hormones and its analogues in preparation of drugs for treating alpha-thalassemia

The present invention provides an application of thyroid hormones and its analogues in preparation of drugs for treating alpha-thalassemia, especially in preparation of drugs for regulating expression of zeta-globin gene. During differentiation of K562 cells, thyroid hormone analogue (Triac) can significantly up-regulate the expression of zeta-globin gene (HBZ) by 50 folds or above. The expression of zeta-globin gene (hbae5) can also be up-regulated by 30-70 folds in zebrafish treated with thyroid hormones and thyroid hormones analogues. Therefore, according to the present invention, the expression of zeta-globin gene can be significantly activated by thyroid hormones and its analogues, which may develop new potential therapies for patients with alpha-thalassemia. It provides an economical, safe and effective method for treating alpha-thalassemia and can be widely used.
Owner:SHANGHAI SPH RARE DISEASE PHARMA CO LTD

Adeno-associated virus compositions for restoring HBB gene function and methods of use thereof

Provided herein are adeno-associated virus (AAV) compositions for correcting a mutation in a beta globin gene (HBB) gene and methods of using the same to correct an HBB gene mutation in a cell. Also provided are packaging systems for making the adeno-associated virus compositions.
Owner:CITY OF HOPE

Method for analyzing and predicting alpha globin gene triad by using high-throughput sequencing data

The invention relates to a method for predicting an alpha globin gene triad by analyzing high-throughput sequencing data, and belongs to the technical field of gene detection.The method comprises the steps that multiple samples are collected and subjected to high-throughput sequencing, read counts A1 and A2 of non-homologous regions of alpha globin genes HBA1 and HBA2 are obtained, and the A2 / A1 ratio is calculated; the method comprises the following steps: analyzing A2 / A1 ratio data to find that the data is in normal distribution, making a histogram for the A2 / A1 ratio data, determining data in an area greater than u + 2sigma as abnormal data in combination with a normal distribution data distribution rule, and judging that an alpha globin gene triad exists in a sample corresponding to the abnormal data. In the subsequent detection sample inspection, whether the alpha globin gene triad exists in the detection sample can be directly judged according to the A2 / A1 ratio, and compared with the verification of a polymerase chain reaction method, the judgment result of the method is consistent with the result of the polymerase chain reaction method; therefore, the method provided by the invention can be directly used for judging the existence of the alpha globin gene triad.
Owner:FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE

Nucleic acid constructs and uses thereof

PCT designated stage expiredWO2025088552A1VectorsHaemoglobins/myoglobinsHumaninGlobin genes
Disclosed herein are gene therapy vectors used for efficiently transducing cells to express a human β-globin gene. Specifically disclosed is an expression vector which comprises: an expression cassette for a β-globin gene, which comprises exons and introns of human β-globin gene, as well as cis-acting elements including one or more of WPRE, SV40 polyadenylation signal and / or SV40 ori. The disclosed expression vectors have significantly enhanced viral vector packaging efficiency in viral vector packaging cell lines, which leads to effective integration of lentiviral vectors and high expression level of β-globin gene in target cells. Also disclosed are pharmaceutical compositions and therapeutic methods utilizing such expression vectors.
Owner:KANGLIN BIOTECHNOLOGY (HANGZHOU) CO LTD

Application of thyroid hormone and its analogs in the preparation and treatment of α-thalassemia

The present invention provides the use of thyroid hormone and its analogs in the preparation of a drug for treating α-thalassemia. Specifically, the drug can be used to regulate ζ-globin gene expression. During K562 cell differentiation, the thyroid hormone analogs can specifically and significantly upregulate the expression of the ζ-globin gene (HBZ) by as much as 50 times. After treatment with thyroid hormone and its analogs in model animal zebrafish embryos, the expression of the ζ-globin gene (hbae5) can also be specifically upregulated by as much as 30-70 times. Therefore, the present invention uses thyroid hormone and its analogs to specifically activate the expression of the ζ-globin gene, that is, to reactivate the silenced ζ-globin gene in α-thalassemia patients to inhibit the destruction of red blood cells. This method provides a method for preparing a drug for treating α-thalassemia, provides an economical, safe and effective method for the treatment of α-thalassemia, and can be widely promoted and used.
Owner:SHANGHAI SPH RARE DISEASE PHARMA CO LTD

Probe, primer, kit and method for detecting alpha-globin gene

The invention relates to a probe, a primer, a kit and a method for detecting an alpha-globin gene. The probe provided by the invention is selected from one or more of the following probes P1 to P4: the probe P1 has a sequence as shown in SEQ ID NO.10; the sequence of the probe P2 is as shown in SEQ ID NO. 11; the sequence of the probe P3 is as shown in SEQ ID NO. 12; the sequence of the probe P4 is as shown in SEQ ID NO. 13. The technical scheme for detecting the genotype of the alpha-globin gene is simple and low in cost.
Owner:SHANGHAI HORIZON MEDICAL SCI CO LTD +1

Corynebacterium glutamicum for synthesizing high-activity heme protein and application of corynebacterium glutamicum

PendingCN120555476ABacteriaHaemoglobins/myoglobinsCoboglobinGlobin genes
The invention provides corynebacterium glutamicum for synthesizing high-activity heme protein and application, and belongs to the technical field of genetic engineering. By enhancing globin gene transcription and optimizing heme prothetic group supply, the synthetic ability of hemoglobin and myoglobin is improved. The corynebacterium glutamicum constructed by the invention can enable the titers of soybean hemoglobin, clover hemoglobin, bovine myoglobin and porcine myoglobin to reach 1.10 g / L, 1.12 g / L, 0.56 g / L and 1.14 g / L respectively during shake flask fermentation, and enables the heme binding rates of produced S-Hb, C-Hb, B-Mb and P-Mb to be improved by 3.64 times, 2.38 times, 1.60 times and 1.49 times respectively, which can be similar to those of naturally extracted standard substances H-Mb and B-Hb.
Owner:JIANGNAN UNIV

Method for reducing cell gene editing large fragment deletion

The invention belongs to the technical field of gene editing, and particularly relates to a method for reducing cell gene editing large fragment deletion. The invention provides a method for reducing cell gene editing large fragment deletion, which comprises the following steps: introducing a gene editing system into a cell, and carrying out gene editing on a gamma-globin gene promoter region so as to reduce HBG gene large fragment deletion, the gene editing system comprises Cas nuclease, gRNA and ssODN, the ssODN comprises a 5'homologous arm, a replacement sequence and a 3 'homologous arm, the length of the 5' homologous arm and the length of the 3 'homologous arm are respectively and independently 30-60 nt, and HBG gene large fragment deletion caused by multiple DSBs can be reduced by adjusting the length of the ssODN.
Owner:GUANGZHOU REFORGENE MEDICINE CO LTD

Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters

PendingUS20260091014A1Amide active ingredientsHereditary MutationBeta thalassemia
Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
Owner:AUGUSTA UNIV RES INST INC

Construction and use of pichia pastoris chassis strain for synthesizing highly active heme proteins

PCT designated stage expiredWO2025000616A1FungiHaemoglobins/myoglobinsPichia pastorisCoboglobin
The present invention relates to the technical field of genetic engineering. Disclosed are construction and use of a pichia pastoris chassis strain for synthesizing highly active heme proteins. In the present invention, a pichia pastoris chassis strain for efficiently synthesizing highly active heme proteins is constructed by enhancing the transcription of globin genes, inhibiting the degradation of globin, and optimizing the supply of heme prosthetic groups. At the shake flask level, the titers of porcine myoglobin, bovine myoglobin, soybean hemoglobin, clover hemoglobin, porcine hemoglobin α subunit, porcine hemoglobin β subunit, Vitreoscilla hemoglobin, and cytochrome P450-BM3 mutant (A82F / A328F) reach 5.02-286.53 mgL-1, and the heme binding rates of these heme proteins reach 13.24%-79.47%. The constructed heme-supplying pichia pastoris chassis strain and strategy in the present invention facilitate synthetization of other highly active heme proteins having a wide application range.
Owner:DONGSHENG BIOTECH (TAIXING) CO LTD +1

Method and composition for activating zeta-globin gene expression

The invention discloses a method and a composition for activating zeta-globin gene expression. The method comprises the step of artificially forming an enhancer element containing an NTG-N (7-8)-WGATAR sequence or an NAA-N (7-8)-WGATAR sequence in a DNA (deoxyribonucleic acid) sense strand or an antisense strand in a promoter region of a zeta-globin gene through homologous recombination repair by using a CRISPR-Cas9 system. The invention also discloses gRNA, ssODN, a composition and a cell, and application of the gRNA, the ssODN, the composition and the cell in preparation of a medicine for treating alpha-thalassemia. According to the method, overexpression of exogenous globin genes is not needed, and the safety risk of gene therapy is reduced. Moreover, expression of the zeta-globin gene is activated, so that the method can be suitable for various types of alpha-thalassemia patients and alpha-gene deletion or mutation patients, and is not limited to alpha-thalassemia caused by a certain mutation site.
Owner:GUANGZHOU REFORGENE MEDICINE CO LTD +1

Method for inducing high expression of delta-globin gene, composition and application

The invention belongs to the technical field of gene editing, and discloses a method for inducing high expression of a delta-globin gene, a composition and application. The invention provides a method for inducing high expression of a delta-globin gene. The method comprises the following steps: artificially introducing a regulation motif into a positive-sense strand or an antisense strand of an HBD gene regulation region through a gene editing technology; the regulation and control motif is at least one of CCNCACCCCT, NTG-N (7-8)-WGATAR and CCAAT (C-CAAT); or at least one of the GGGTGNGG, the YTATCW-N (7-8)-CAN and the ATTGG. The HBD gene is edited by using a gene editing technology to induce high expression of the delta globin. And overexpression of exogenous globin genes is not needed, so that the safety risk of gene therapy is reduced. And the method can be suitable for diseases caused by various types of beta-hemoglobin deletion or mutation, and is not limited to diseases caused by a certain mutation site.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV +1

A method for predicting α-globin gene triplets using high-throughput sequencing data analysis

The present invention relates to a method for predicting α-globin gene triplets by analyzing high-throughput sequencing data, belonging to the field of gene detection technology. The present invention collects multiple samples and performs high-throughput sequencing on the multiple samples to obtain read counts A1 and A2 of the non-homologous regions of the α-globin genes HBA1 and HBA2, and calculates the A2 / A1 ratio. By analyzing the A2 / A1 ratio data, it is found that the data is normally distributed. Then, a histogram of the A2 / A1 ratio data is made. In combination with the distribution law of normally distributed data, data within the region greater than u+2σ is identified as abnormal data, and the presence of α-globin gene triplets in the samples corresponding to the abnormal data is determined. In subsequent sample testing, the presence of α-globin gene triplets in the test samples can be directly determined based on the A2 / A1 ratio. The method of the present invention has been verified and compared with the polymerase chain reaction method. The determination results of the present invention are consistent with the results of the polymerase chain reaction method, indicating that the method of the present invention can be directly used to determine the presence of α-globin gene triplets.
Owner:FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE

Prime editing of the -115 region in the HBG1 and / or HBG2 promoter for increasing fetal hemoglobin content in a eukaryotic cell

PCT designated stage expiredWO2025017033A1Haemoglobins/myoglobinsHydrolasesCoboglobinPhysiology
β-hemoglobinopathies, β-thalassemia and sickle cell disease (SCD), are monogenic diseases caused by mutations in the β-globin locus, affecting the synthesis or the structure of the adult hemoglobin (Hb). It has been shown that the severity of both SCD and β-thalassemia is lessened by the hereditary persistence of fetal hemoglobin (HbF) in adulthood (HPFH). Now the inventors exploited the capacity of prime editing to simultaneously generate multiple HPFH mutations and disrupt the BCL11A repressor BS in the -115 region of the HBG1 / 2 γ-globin promoters to further boost HbF expression and correct the β-thalassemia and SCD phenotypes. Specifically, the inventors selected two potent HPFH / HPFH-like mutations generating BSs for the GATA1 and KLF1 activators, that are associated with a strong γ-globin reactivation in patients and experimental models. This strategy would be very appealing for the treatment of β-hemoglobinopathies.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

A method and device for detecting alpha-globin gene copy number variation

A method and device for detecting alpha-globin gene copy number variation, the method comprising: a primary detection step, comprising predicting whether the sample to be detected exists alpha-globin gene deletion according to the overall feature matrix of the sequencing data of the sample to be detected; a secondary detection step, comprising analyzing the alpha-globin gene copy number of the sample to be detected according to the prediction result of the primary detection step; and a tertiary detection step, comprising analyzing the accurate type of the alpha-globin gene copy number variation of the sample according to the prediction result of the secondary detection step. The present application constructs a combined model for identifying alpha-globin copy number variation, which can quickly and accurately identify the type of alpha-globin copy number variation including triplets using high-throughput sequencing data.
Owner:TIANJIN MEDICAL LAB BGI +1

Genetic test kit for detecting thalassemia

One aspect of the invention is a method for amplifying alpha globin genes HBA1, HBA2 and HBA12 in a single PCR tube to determine an HBA genotype of a subject. This method employs five primers selected to accurate and sensitively identify the HBA1, HBA2, and HBA12, a gene found at a higher frequency in citizens of Saudi Arabia, by accurately annealing to nucleic acids in a biological sample and simultaneously amplifying sequences encoding the alpha globin genes. This invention includes a procedure and required reagents for the amplification of alpha globin genes in a single PCR tube.
Owner:IMAM ABDULRAHMAN BIN FAISAL UNIV

Method and composition for activating zeta-globin gene expression

The invention discloses a method and a composition for activating zeta-globin gene expression. The method comprises artificially forming an enhancer element comprising an NTG-N (7-8)-WGATAR sequence, an NAA-N (7-8)-WGATAR sequence, a YTATCW-N (7-8)-CAN sequence and / or a YTATCW-N (7-8)-CTN sequence on a sense strand or an antisense strand of a non-coding region of a zeta-globin gene by using a gene editing technique. The invention also discloses gRNA, ssODN, a composition and a cell, and application of the gRNA, the ssODN, the composition and the cell in preparation of a medicine for treating alpha-thalassemia. According to the method, overexpression of exogenous globin genes is not needed, and the safety risk of gene therapy is reduced. Moreover, expression of the zeta-globin gene is activated, so that the method can be suitable for various types of alpha-thalassemia patients and alpha-gene deletion or mutation patients, and is not limited to alpha-thalassemia caused by a certain mutation site.
Owner:GUANGZHOU REFORGENE MEDICINE CO LTD

Polynucleotide construct for gene therapy of beta-hemoglobinopathies

The present invention relates to a polynucleotide construct comprising a hemoglobin subunit alpha-hemoglobin subunit beta (HBA-HBB) hybrid gene construct for enhancing the potency of gene therapy for the β-hemoglobinopathies, particularly β-thalassemia and sickle cell disease (SCD). The polynucleotide construct comprising elements that are operatively connected to each other in the following sequence: HBB locus control region (HBB-LCR), HBA promoter, and β-like globin gene. Additionally, the HBA-HBB gene construct further comprises a microRNA-based short hairpin RNA (shRNAmir) targeting one of the endogenous HBA or HBB genes to increase the ratio of vector-encoded HBBT87Q to endogenous HBA and β-like globin chains while maintaining high vector titers.
Owner:IMPLEMENT GT CO LTD

Method and kit for detecting alpha and beta globin gene copy number and tiny variation and application thereof

The invention discloses a method and a kit for detecting copy number and tiny variation of an alpha-globin gene and a beta-globin gene and application of the method and the kit. An alpha-globin gene and a beta-globin gene are amplified at the same time in a single-tube PCR reaction, and as many as 61 deletion or repetition types such as normal types, 8 heterozygous deletion types, 36 homozygous deletion types, 2 repetition types, 14 composite heterozygous deletion / repetition types and the like can be detected at a time. Meanwhile, three types of non-deletion type alpha-thalassemia and 18 types of non-deletion type beta-thalassemia can be respectively detected, and normal, heterozygous and homozygous mutations can be distinguished. According to the method, deletion, repetition and tiny variation detection of alpha and beta-thalassemia can be achieved only through one-time PCR, the process is simple, standardization is easy to achieve, meanwhile, the detection time is greatly shortened, and integrity detection is provided for thalassemia.
Owner:XIAMEN BIOFAST BIOTECHNOLOGY CO LTD

Nucleic acid constructs and uses thereof

PendingCN122070147AVectorsHaemoglobins/myoglobinsBeta globinGlobin genes
Disclosed herein are gene therapy vectors for efficient transduction of cells to express human beta globin genes. Specifically disclosed is an expression vector comprising: an expression cassette of a beta globin gene comprising an exon and an intron of a human beta globin gene, and a cis-acting element comprising one or more of WPRE, an SV40 polyadenylation signal and / or SV40 ori. The disclosed expression vectors have significantly enhanced viral vector packaging efficiency in viral vector packaging cell lines, which results in efficient integration of lentiviral vectors in target cells and high expression levels of beta globin genes. Pharmaceutical compositions and methods of treatment utilizing such expression vectors are also disclosed.
Owner:KANGLIN BIOTECHNOLOGY (HANGZHOU) CO LTD

Construction method and application of globin gene humanized mouse beta-thalassemia CD17 point mutation animal model

The invention discloses a construction method and application of a globin gene humanized mouse beta-thalassemia CD17 point mutation animal model, by utilizing a guide editing technology, an epegRNA sequence (independently designed sequences mainly comprise spacer, PBS, RT and 1inner sequences) of a targeted HBB gene CD17 site, a candidate ngRNA sequence and an mRNA combination of an enzyme of PE are autonomously constructed, and by utilizing a micro-injection mode, a CD17 point mutation animal model of the HBB gene humanized mouse beta-thalassemia CD17 point mutation animal model is constructed. Injecting the combined system to 1-2 cell stage fertilized eggs of Townes mice, transplanting the fertilized eggs to receptor pseudopregnant mice, after the mice are delivered to F0-generation mice, quantitatively analyzing targeted site point mutation mice by using an NGS sequencing technology, and hybridizing to obtain hybrid site mutation F1-generation mice from CD17AAG to TAG. The mouse is used as a classical animal model for in-depth study of a beta-thalassemia pathogenic mechanism, beta-thalassemia targeted drug screening and gene therapy study of point mutation precise repair.
Owner:FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE

Kits and methods for determining geno type of thalassemia

PendingUS20260185160A1MedicineGene cluster
Provided herein are kits and methods for determining a thalassemia genotype of a subject. The present kit includes at least primers that target ζ2, Ψζ1, Ψα2, Ψα1, α2, α1 and θ1 genes in α-globin gene cluster, and primers that target variations in α2-globin gene and β-globin gene. Also encompasses herein is a method for determining a thalassemia genotype of a subject, in which gene copy number of each target sites in ζ2, Ψζ1, Ψα2, Ψα1, α2, α1 and θ1 genes in α-globin gene cluster are determined by use of the present kit, and compared with those of normal or known thalassemia subject to arrive at the thalassemia genotype of the subject.
Owner:ORIGIN BIOTECHNOLOGY CO LTD